Latham & Watkins LLP represented Aligos Therapeutics, while Davis Polk advised the representatives of the several underwriters in the offering. Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced...
Aligos Therapeutics’ $83.6 Million Public Offering
REV Group’s $85.3 Million Stock Offering
Davis Polk advised REV Group, Inc. and certain selling stockholders in the offering. The secondary offering consisted of 5,500,000 shares of common stock by such selling...